Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) PT Raised to $87 at Leerink Partners

October 30, 2024 6:26 AM EDT

Leerink Partners analyst Andrew S. Berens raised the price target on Incyte (NASDAQ: INCY) to $87.00 (from $85.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: This morning, Incyte reported 3Q24 financial results and provided updates on the pipeline. INCY beat consensus on key product revenues, with... More

Incyte (INCY) PT Raised to $97 at Citi

October 30, 2024 5:47 AM EDT

Citi analyst David Lebowitz raised the price target on Incyte (NASDAQ: INCY) to $97.00 (from $92.00) while maintaining a Buy rating.

The analyst comments "Incyte reported 3Q24 results, delivering topline revenue beats due to sustained growth for key franchise drivers in Jakafi and... More

Incyte (INCY) PT Raised to $84 at Jefferies

October 29, 2024 2:41 PM EDT

Jefferies analyst Kelly Shi raised the price target on Incyte (NASDAQ: INCY) to $84.00 (from $81.00) while maintaining a Buy rating.

The analyst comments "INCY delivered great Q with rev beat ($1.14B vs $1.08B cons) all around - Jakafi $741M (+5% QoQ vs $718M cons) and... More